case western reserve university

Page Expired


The page you are attempting to view may be out-of-date.

The page in question has not been verified by its author in quite some time.

If the information provided on the page is time sensitive, it is possible that it is no longer accurate. To ensure that you receive the most current information, we recommend you contact the page's author. He or she can verify whether the information is correct and/or direct you to a more up-to-date page.

Continue to the requested page.

ogy-based therapies, for example, will redefine disease treatment. "The vision is, your body can generate your own drug—a protein with the properties necessary to correct for your particular defect."

All of these advances rely on continuing rapid progress in technology, experts note. Ultra-sophisticated computers are needed, for example, to lead scientists to those exceptional DNA characteristics that have meaning for a person's health. (See "Computers as Key" on page 15.)


Though early inroads have been made in creating living replacements to repair or replace damaged cells and tissues, figuring out a biological fix for the problems caused by aging and disease is a long-term venture. Perhaps, within a century, simple treatments will be developed based on gene transfer or cell (including stem cell) transplantation.

Presaging Baby Boy's susceptibility to heart disease is one thing, but it's only helpful if methods are available to lessen the risk of damage or repair that is discovered. The good news for him: Within 100 years, researchers expect to be able to generate tissues made from a person's own DNA—"no need to obtain someone else's heart or eyes or kidneys like we do today," Jain forecasts. And no need for artificial organs, when a heart for Baby Boy—and blood vessels to feed the organ— can be grown in a petri dish based on his own molecular makeup.

"To my way of thinking, cardiovascular disease is solvable within a century by cell replacement," says Horst von Recum, PhD, assistant professor of biomedical engineering, who studies how stem cells become cardiac or other cells that perform a specific function. "If we can make new heart tissue by replacing cells, heart failure from heart attack or tissue death can become largely a health problem of the past: Get to someone fast enough, and they needn't die."

For all its intricacy, heart disease is a straightforward challenge compared with cancer or neurological disorders, notes von Recum, based on the complexities of the latter conditions themselves and the organs that are compromised. Still, von Recum says, a century's progress in cell therapy is also sure to fortify the armory for facing down these conditions, as well as spinal cord injuries and other neurological conditions that stymie today's scientists.


About a decade after a Super Bowl ad showed Christopher Reeve walking—while in reality the late actor and activist remained wheelchairbound from a devastating spinal cord injury— the commercial is still remembered for the controversy it caused, some saying it raised false hopes that a cure for paralysis was within reach. Is a cure likely to be found, even in the next century, to allow people with severe spinal cord injuries to walk again?

A team of researchers, including Peckham and other university experts in biomedical engineering and medicine, has already figured out how to restore lost abilities such as grasping, standing and coughing less severely to some paralyzed patients. The concept: produce an artificial nervous system of sorts within the body that mimics the natural one, using electrical signals sent by an external computer to substitute for the signals that in a working nervous system would travel directly from the brain or spinal cord.

Peckham, who is now collaborating with other biomedical engineering experts on a fully implanted "network neural prosthesis" (NNP) to restore multiple functions to a person with paralysis, hopes that within 50 years this technology, combined with other things like biological restoration and exercise approaches, will see people with "fairly severe cervicallevel spinal cord injuries" able to stand, use their hands, have good balance and move from one surface to another, such as from a wheelchair to a bed.

Anticipated use of the implantable device, Peckham emphasizes, is not limited to spinal cord injury, but is likely to be expanded to stroke and other neurological disorders. And conceptually, the device could be triggered to deliver a drug, along with the electrical current to the brain, whenever a tremor occurs. But what of enabling someone with Christopher Reeve-extent injuries to walk? According to Peckham, such an accomplishment could take decades to fully achieve.

In company with Peckham in the promising efforts to restore function and independence to those with paralysis is neuroscientist and School of Medicine professor Jerry Silver, PhD, whose two recent breakthroughs in biological therapies have so far worked in biologic models and in 100 years may translate into greatly improved health and autonomy for the thousands of people paralyzed each year.

In one experiment, Silver sent signals through severed spinal cords and restored breathing by shining pulses of light from a light-sensitive protein cloned from algae. In another study, Silver re-established nerve connections and restored some movement in biologic models with partial paralysis by grafting a piece of the sciatic nerve to the spinal cord and inducing nerve fibers to produce a gap-filling neural "bridge," and also delivering the enzyme chondroitinase to the site to prevent additional scarring.

Based on these and other promising studies of potential paralysis treatments, Silver predicts that within 100 years, "We may have the expertise to fairly simply restore function of some simple muscles, help people get off their respirator and breathe on their own, and return their bladder function."


Since the discovery of the x-ray more than a century ago, imaging has allowed a noninvasive look-see into the human body for clues about disease or injury. But current medical diagnoses can miss the mark because of incomplete information from x-ray and even other, more sophisticated 2011 imaging technologies.

Even with MRI, x-ray computed tomography, ultrasound and other imaging technologies that are available for modern medical diagnosis, current imaging methods, overall, are crude compared with the expert-predicted imaging methods of the next century. "A hundred years is a long time, and what seems far-out now could become reality in that timeframe," says Jeffrey Duerk, PhD, chair of Case Western Reserve's biomedical engineering department and director of the Case Center for Imaging Research. "Imaging could resemble a Star Trek episode, where they run a wand over somebody's head and uncover a huge aneurysm."

Diagnostic capability may be redefined within a century, Duerk says, by imaging's emerging ability to detect specific molecular interactions occurring inside the body and unambiguously characterize a pathology. In the case of a would-be cancer patient, according to the biomedical engineer, "I believe we will be able to detect the earliest cellular and molecular changes before the patient goes on to actually develop a tumor, with imaging contrast agents and advanced imaging systems, designed together to provide the required sensitivity." In Baby Boy's case, the ultramodern methods could spare him the discomfort of cardiac cauterization to capture particularized pictures of his heart. "Within 100 years, imaging devices will provide much higher spatial and temporal resolution," Duerk predicts. "We may be able to routinely see the entire beating heart at an ultra-detailed 1,000 frames per second."

Advanced imaging techniques being researched today will support new treatments within a century where adequate therapies are so far lacking, Duerk foresees, by exposing early whether experimental treatments are effective or failing. For Alzheimer's disease, is a treatment combating the implicated plaques and tangles? In multiple sclerosis, how well is the myelin being repaired? If a treatment being studied—or one used therapeutically—isn't working, says Duerk, "We'll be able to stop and move on to something with greater possibility earlier."


Vaccines have already achieved sweeping success in infectious disease control in the U.S. and around the world. Credited for the eradication of smallpox, the elimination of polio in much of the world, and the dramatic decline in diphtheria, whooping cough and measles, immunizations are the best hope over the next 50 to 100 years for gaining the upper hand on communicable disease threats.

Will we ever be able to cure HIV infection? It's a question that has been put repeatedly to Michael Lederman, MD, since soon after HIV was identified in the early 1980s. "I used to be very pessimistic," recalls Lederman, co-director of Case Western Reserve/UH Case Medical Center's Center for AIDS Research and the Scott R. Inkley Professor of Medicine. "But based on new inroads, it's plausible we could eradicate HIV at some point in the future." For now, notes global infectious disease expert James Kazura, MD, who heads up the school's Center for Global Health and Diseases, "The fantastic antiretroviral drugs available today in the United States have turned HIV into a chronic disease."

Not so in the developing world, including Africa, Kazura is quick to point out. As an influential country in the global community— and with its population always susceptible to additional infectious diseases such as swine flu and avian flu—the United States will increasingly focus, over the next century, on finding cost-effective solutions to globally significant infectious diseases including HIV, tuberculosis and malaria, Kazura says. He and Lederman agree: In the next century, there may be a very effective immunization not only for HIV, but TB and malaria. Eradication around the world, however, is something that neither expert is counting on.

While HIV and some other current health challenges may well be controlled, new diseases are bound to pop up in their place, school experts caution, as various microbes evolve to outwit prevention efforts. According to Lederman, "It's a constant race between us and the bugs—their genetic selection versus our scientific smarts."


Add to bugs' wily evolution another challenge to medical progress: the complexities of human nature. Behavioral changes, experts point out, are in some cases required to realize the promise of advances in medical understanding. Chance illustrates, "Say your gene sequence says that if you smoke, you'll have a 95 percent chance of getting lung cancer in a certain timeframe. Having this 'answer' doesn't mean behaviors will change and that health will improve."

"The trouble with the current advice to avoid high-fat foods, cigarette smoking and other risk factors for disease," expands Miller, "is we're talking about statistic susceptibility: If you smoke, you're more likely to get lung cancer. People can cop out, saying 'Doesn't mean me.' Not so if you tell someone, 'If you smoke, you will get lung cancer by age 30.'"

Based on this important distinction, some researchers express hope that the ability to provide personal—not only statistical— information about disease risk will motivate behavior change in those who, like Baby Boy, have a high risk of a disease that lifestyle changes could abate.

Given all these incalculable variables, Lederman sums up the exercise of foretelling the state of medicine in a century: "It's hard to predict the pace and path of science." But one thing, he says, is observed across the whole history of medical discovery: "Some things happen at a slow and measurable rate, then all of a sudden there's a huge breakthrough observation that changes the rules. Slow and steady progress is vital, but big paradigm shifts are the things that transform medicine." If school prognosticators are right, these metamorphoses could be driven by newscience disciplines such as genomics and regenerative medicine, as well as modernized approaches to imaging and infectious disease control.

Share bookmark or share